Venus Remedies Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Intraday Price Movement and Circuit Breaker Trigger

On 25 Feb 2026, Venus Remedies Ltd’s share price plunged to an intraday low of ₹674.50, representing a 4.99% drop from the previous close. The stock’s price band was set at 5%, and the fall of ₹21.05 triggered the lower circuit, effectively halting further declines for the day. This marked the maximum permissible daily loss, underscoring the severity of the selling pressure. The weighted average price for the day was closer to the low end, indicating that most trades occurred near the bottom of the price range.

Volume and Liquidity Analysis

Trading volumes were moderate, with a total traded volume of approximately 51,562 shares (0.51562 lakhs) and a turnover of ₹3.50 crore. Despite the sharp price fall, the stock maintained reasonable liquidity, supporting trade sizes up to ₹0.04 crore based on 2% of the five-day average traded value. Notably, delivery volumes on 24 Feb rose by 50.78% compared to the five-day average, signalling increased investor participation, albeit amid a bearish sentiment.

Sector and Market Context

Venus Remedies Ltd underperformed its Pharmaceuticals & Biotechnology sector, which gained 0.90% on the same day, and the broader Sensex, which rose 0.82%. The stock’s one-day return of -2.99% contrasted sharply with the positive sector and market movements, highlighting company-specific challenges or negative sentiment driving the sell-off. Over the past five trading sessions, the stock has declined by 13.3%, reflecting sustained downward momentum.

Technical Indicators and Moving Averages

From a technical standpoint, Venus Remedies Ltd’s share price remains above its 100-day and 200-day moving averages, suggesting some underlying long-term support. However, it is trading below its 5-day, 20-day, and 50-day moving averages, indicating short- to medium-term weakness and a bearish trend. The intraday volatility was high at 5.8%, reflecting significant price swings and uncertainty among traders.

Fundamental and Market Capitalisation Overview

Venus Remedies Ltd operates within the Pharmaceuticals & Biotechnology industry and holds a micro-cap market capitalisation of approximately ₹905 crore. The company’s Mojo Score stands at 70.0, with a current Mojo Grade of Buy, downgraded from Strong Buy as of 1 Feb 2026. The Market Cap Grade is rated 4, reflecting its relatively small size but potential for growth. This downgrade signals a cautious stance by analysts, likely influenced by recent price weakness and market dynamics.

Investor Sentiment and Panic Selling

The stock’s five-day losing streak and the triggering of the lower circuit suggest panic selling and unfilled supply overwhelming demand. The sharp intraday fall and high volatility indicate that investors are offloading shares aggressively, possibly due to concerns over company fundamentals, sector headwinds, or broader market uncertainties. The inability of buyers to absorb the selling pressure has resulted in the circuit filter being hit, a rare event that highlights extreme market sentiment.

Outlook and Strategic Considerations

While the stock’s long-term moving averages provide some technical support, the short-term trend remains negative. Investors should closely monitor upcoming corporate announcements, sector developments, and broader market conditions before making fresh commitments. The downgrade from Strong Buy to Buy reflects a tempered outlook, suggesting that while the company retains growth potential, risks have increased in the near term.

Comparative Performance and Peer Analysis

Compared to its sector peers, Venus Remedies Ltd’s recent performance has been disappointing. While the Pharmaceuticals & Biotechnology sector has shown resilience with positive returns, Venus Remedies has lagged significantly. This divergence may be attributed to company-specific issues such as earnings concerns, regulatory challenges, or competitive pressures. Investors should weigh these factors against the broader sector outlook before adjusting their portfolios.

Conclusion: Navigating Volatility and Risk

Venus Remedies Ltd’s lower circuit hit on 25 Feb 2026 underscores the heightened volatility and selling pressure facing the stock. The maximum daily loss of nearly 3% and the five-day cumulative decline of over 13% reflect a period of significant investor anxiety. While the stock retains a Buy rating with a Mojo Score of 70.0, the recent downgrade and technical weakness advise caution. Market participants should remain vigilant, monitor volume trends and price action closely, and consider the company’s fundamentals in the context of sector and market conditions before making investment decisions.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →